unknown
Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study
- Publication date
- 1 January 2010
- Publisher
- European Association for the Study of the Liver